Research programme: cancer therapeutics - Debiopharm/EPFL

Drug Profile

Research programme: cancer therapeutics - Debiopharm/EPFL

Alternative Names: Debio 0826

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Debiopharm
  • Developer Debiopharm; Swiss Federal Institute of Technology - Lausanne
  • Class Peptides; Small molecules; Venoms
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Cancer in Switzerland
  • 15 Apr 2011 Debio 0826 is still in early research for Cancer in Switzerland
  • 02 Sep 2008 Early research in Cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top